Aclaris Bosakitug Misses Primary Endpoint in Dermatitis

Aclaris Therapeutics reported Phase 2 ADMIRATION trial results for its anti-TSLP antibody bosakitug in moderate-to-severe atopic dermatitis.

Updated on Nov. 16, 2026 in Biotech

Vector-style editorial illustration of unlabeled flasks with amber liquid on a steel lab bench, with one clear tube set apart, conveying a clinical trial setback.
Aclaris Therapeutics said its anti-TSLP antibody bosakitug missed the primary endpoint in a Phase 2 atopic dermatitis trial, while the drug was generally well tolerated. AI Illustration. Upload story photo >

Aclaris Therapeutics, based in Wayne, Pa., announced top-line Phase 2 results for bosakitug, an anti-TSLP monoclonal antibody, in patients with moderate-to-severe atopic dermatitis. The ADMIRATION trial did not achieve its primary endpoint of percent change in EASI score from baseline at week 24, nor its secondary endpoints.

Why it matters

The miss is a setback for Aclaris's lead dermatology candidate, while pharmacodynamic data showing TSLP target engagement and reduced Th1, Th2 and Th17 biomarkers offer some mechanistic information. The company is shifting attention to its broader pipeline, including oral and bispecific programs.

The Phase 2 ADMIRATION trial missed its week 24 primary EASI endpoint and all secondary endpoints, while pharmacodynamic analyses confirmed TSLP target engagement and downregulation of Th1, Th2 and Th17 biomarkers. The source does not disclose effect sizes, sample size or the reasons for the endpoint miss.

The players

Aclaris Therapeutics, Inc.

Aclaris Therapeutics is a biopharmaceutical company based in Wayne, Pennsylvania, developing immunology and dermatology therapies including bosakitug and modzatinib.

The details

Bosakitug was generally well tolerated in the trial, according to Aclaris. The company said the results will inform its next steps for the anti-TSLP program, which it is advancing alongside an oral ITK/JAK3 inhibitor in lichen planus and an anti-TSLP/IL-4Rα bispecific antibody.

Timeline

  1. Q1 2027: Aclaris plans to initiate a Phase 2b trial of ATI-052 in eosinophilic esophagitis.

  2. Q4 2026: Aclaris expects to file an IND for oral ITK inhibitor ATI-9494 this quarter.

  3. Throughout 2027: Aclaris expects regulatory, clinical and data milestones across its assets.

The Tech Race

Bosakitug's miss adds to scrutiny of anti-TSLP antibodies in atopic dermatitis, a class that drew interest as a potential upstream blocker of multiple inflammatory pathways. Aclaris's pivot toward oral ITK/JAK3 and bispecific TSLP/IL-4Rα programs reflects an industry effort to find differentiated approaches in the crowded dermatology market.

For people living with moderate-to-severe atopic dermatitis, the bosakitug result means this candidate will not reach the market on its current path. Patients and clinicians will continue to rely on existing approved treatments while newer pipeline candidates are tested.

The takeaway

Failed Phase 2 readouts are common in drug development, and the pharmacodynamic data here show the drug hit its biological target even though clinical benefit was not shown. Investors and patients should watch how Aclaris's next trials and IND filings build on that mechanistic information.

What happens next

Aclaris expects to file the IND for oral ITK inhibitor ATI-9494 this quarter and to start the ATI-052 Phase 2b trial in eosinophilic esophagitis in the first quarter of 2027.

Further reading

Explore more Biotech coverage for context on drug development setbacks and pipeline strategy.

Source note: This article includes information reported by The Manila times.